CFB
XLO icon

Cullen/Frost Bankers’s Xilio Therapeutics XLO Stock Holding History

Cullen/Frost Bankers’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7
Closed -$55 – 1104
2023
Q4 		$55 Hold
7
– – ﹤0.01% 1009
2023
Q3 		$211 Buy
+7
New +$261 ﹤0.01% 1138

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cullen/Frost Bankers's XLO Position: Q1 2024 in Review

Cullen/Frost Bankers sold out of Xilio Therapeutics (XLO) in Q1 2024, closing a stake of 7 shares — an estimated $55 sold.

Cullen/Frost Bankers first reported a position in XLO in Q3 2023 and held it in 2 quarters. The position peaked at $211 in Q3 2023. 30 funds tracked by Wall St. Rank hold XLO as of Q1 2024.

  • Cullen/Frost Bankers reported no remaining Xilio Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cullen/Frost Bankers sold 7 Xilio Therapeutics shares in Q1 2024, an estimated $55.
  • Cullen/Frost Bankers first reported a position in Xilio Therapeutics in Q3 2023 and held it in 2 quarters.
  • Cullen/Frost Bankers's Xilio Therapeutics position peaked at $211 in Q3 2023.
  • 30 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2024.

Based on Cullen/Frost Bankers's 13F filing for Q1 2024, filed 10 May 2024.